- About us
- About Vaccines
- Media centre
- Become a member
- VE Day 2013
Vaccines Europe represents all the major vaccine companies operating in Europe which undertake 79% of their global production and more than 50% of their global research projects in the region.
Today is World Meningitis Day. It is estimated that every year more than 1.2 million people are affected by meningitis all around the world. Meningitis is inflammation of the meninges, the covering of the brain and spinal cord. It is most often caused by infection (bacterial, viral, or fungal), but can also be produced by chemical irritation, subarachnoid haemorrhage, cancer and other conditions. Meningitis is a serious disease that can affect anyone across all ages. According to the World Health Organisation (WHO) it is fatal in 50% of cases if untreated, and may result in brain damage, hearing loss or learning disability for survivors. Read more…
This week is European Immunisation Week. Immunisation is indeed considered one of the most cost-effective public health interventions available and the WHO estimates that it saves between 2 to 3 million lives every year. Vaccines has however become victims of their own success, and with the drop-down and disappearance of several diseases thanks to vaccination programmes many people who no longer see public health risks decide not to vaccinate. Over the past years, this has resulted in several severe outbreaks in European countries of vaccine preventable diseases putting avertable strains on health and healthcare systems. According to the WHO, “2013 saw 31865 measles cases alone in Europe, an increase of 348% compared to 2007. The cost of these outbreaks in both human and monetary terms is extremely high”. Read more…
Vaccines Europe (VE), The European Vaccine Initiative (EVI), The Sclavo Vaccines Association (SVA) and EATRIS due to meet in Brussels for penultimate workshop ahead of the final project summit with top stakeholders in the vaccine field.
Key opinion leaders in the field of vaccine research and development are meeting in the upcoming IPROVE consultation workshop in Brussels on 12 and 13 March 2015. The objective of the workshop is to formulate a consensus on future vaccine R&I activities and identify key gaps and needs to be addressed over the coming years to bolster vaccine innovation and connect across Europe the appropriate expertise needed to meet the challenge of current medical needs. Read more…